Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
The combination therapy of Eisai’s orally administered tyrosine kinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) failed to meet the primary endpoints in a PIII trial, dubbed LEAP-002, targeting patients with unresectable hepatocellular carcinoma (HCC), the two…
To read the full story
Related Article
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
- Ribomic, Fujifilm to Join Forces on LNP CDMO Services
July 7, 2026
- Toray Unveils Next-Generation Opioid Painkiller Candidate
July 7, 2026
- Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…